Diabetic Retinopathy Market: Current Analysis and Forecast (2023-2030)

Diabetic retinopathy is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. As the global population ages, the incidence of diabetic retinopathy is expected to rise, thus fueling the demand for treatment options. The rising awareness about diabetic retinopathy also plays a significant role in driving growth in the diabetic retinopathy market. Increased awareness efforts by government health agencies, non-profit organizations, and healthcare providers have raised public consciousness about the importance of regular eye examinations for individuals with diabetes. Additionally, technological advancements in drug development have increased in recent years further driving the market growth.

The Diabetic Retinopathy Market is expected to grow at a strong CAGR of 9.1% during the forecast period owing to the rising geriatric population. For instance, according to the U.S. Census Bureau, the global population aged 65 and older will reach 1.6 billion by 2050, more than double the population in 2018. Similarly, the World Health Organization (WHO) estimates that the number of people aged 60 and above will nearly triple by 2050, from 962 million in 2017 to 2.1 billion. These statistics indicate a significant increase in the geriatric population worldwide. Spreading awareness about the disease is very crucial to help patients diagnose the disease in early stages and search for appropriate medical treatment. Driving factors contributing to the development and progression of diabetic retinopathy are longer duration of diabetes, poor blood sugar control, high blood pressure, elevated cholesterol levels, smoking, family history, and genetic predisposition. The surge in poor lifestyles also contributes to the growth of the diabetic retinopathy market.

Based on types, the market is bifurcated into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. The non-proliferative diabetic retinopathy segment held the majority share of the market in 2022 because of the higher prevalence of the disease in recent years. In non-proliferative diabetic retinopathy, the small blood vessels in the retina are damaged due to prolonged exposure to high levels of blood sugar. However, if the condition progresses, patients experience blurred vision, difficulty reading, and difficulty in differentiating colors. Growing cases of diabetes are leading to the growth of the disease worldwide. Hence, the non-proliferative diabetic retinopathy category held the majority share of the market in the year 2022 during the forecast period.

Based on application, the market is bifurcated into diagnosis and treatment. The treatment segment is expected to grow at a significant rate in the forecast period. The driving factor for the treatment segment is the growing technological advancements. The growth of the treatment segment in the diabetic retinopathy market is driven by increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Continued investment in research and development, along with efforts to improve patient access to effective treatments, will likely sustain the growth trajectory of the treatment segment in the forecast period. Thus, the treatment segment is expected to gain prominence in the market in the forecast period.

For a better understanding of the market adoption of the rare hemophilia factors industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market of diabetic retinopathy in 2022. Several factors such as the growing cases of diabetic retinopathy, availability of innovative generics, growing awareness of diabetic retinopathy, company collaborations, and the rising geriatric population in the region are driving the market in the region. For instance, there were 8.94 million people aged >=40 years with diabetic retinopathy and 1.71 million people aged >=40 years with vision-threatening diabetic retinopathy. North America dominated the diabetic retinopathy market among regions in the year 2022.

Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; Novartis AG; Regeneron Pharmaceuticals Inc.; Bayer AG; Coherus BioSciences, Inc.; KODIAK SCIENCES INC.; HANLIM PHARM.CO.LTD.; Sanofi; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.